HOME >> BIOLOGY >> NEWS
JCI table of contents: July 12, 2007

EDITOR'S PICK

Src inhibitors may prove beneficial in breast cancer therapy

Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development. However, one-third of new breast cancers lack detectable ER-alpha. These ER-alphanegative cancers are more aggressive and have a worse prognosis than do ER-alphapositive breast cancers, and have been thought to be estrogen independent. In a study appearing online on July 12 in advance of publication in the August print issue of the Journal of Clinical Investigation, Joyce Slingerland and colleagues from the University of Miami shed further light on the mechanisms regulating ER-alpha expression levels during breast cancer.

In their study of 250 primary breast cancers, the authors found that ER mRNA levels overlap considerably between ER-alphapositive and ER-alphanegative breast cancers. This lack of correlation between ER-alpha mRNA and protein levels pointed to the existence of important post-transcriptional control of ER-alpha expression. They found that ER-alphanegative primary breast cancers and cell lines showed increased levels and/or activity of the protein Src, which cooperates with estrogen to activate ER-alpha breakdown via proteolysis. In line with this finding, Src inhibition was shown to impair estrogen-stimulated ER-alpha proteolysis. The data raise the possibility that for at least a subset of ER-alphanegative breast cancers, Src may stimulate estrogen-dependent ER-alpha degradation, resulting in a lack of ER-alpha detection, and more aggressive tumor growth. The authors conclude that their study provides a rationale for the use of Src inhibitors in breast cancer therapy.

TITLE: Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer

AUTHOR CONTACT:
Joyce M. Slingerland
University of Miami Miller School of Medicine, Miami, Florida, USA.
Phone : (305) 243-7265;
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
12-Jul-2007


Page: 1 2 3 4 5

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: June 21, 2007
9. JCI table of contents: June 14, 2007
10. Food safety begins as vegetables grow
11. Turning the tables in chemistry

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/11/2019)... ... 10, 2019 , ... Improved Pharma LLC announces the publication of “Predictive and ... The article was published online on April 29th, 2019. The authors are Stephen ... Chen of Purdue University. , The article is the most recent addition to a ...
(Date:6/6/2019)... ... June 05, 2019 , ... Pelican BioThermal , ... station and service center in Mexico City, Mexico. Mexico is the second largest ... more than $1.75 billion in pharmaceutical exports since 2015. The Mexico City network ...
(Date:6/4/2019)... ... June 04, 2019 , ... In’Tech Medical SAS ( ... Q1-19 revenues of $31M, up 12% from Q1-18. The growth is associated with ... & operational excellence initiatives worldwide. , Laurent Pruvost , President & CEO ...
Breaking Biology News(10 mins):
(Date:4/25/2019)... ... 24, 2019 , ... Inference Solutions , a global ... announced global availability of Inference Studio’s latest version, which makes it easier for ... the power of Google’s Contact Center AI (CCAI). , As consumers ...
(Date:4/16/2019)... ... April 16, 2019 , ... On April 24th, the Federal ... Army Center for Environmental Health Research (USACEHR), with an award for their cooperative ... a veteran-owned company located at the Frederick Innovative Technology Center, Inc. (FITCI) on ...
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, Inc., a developer ... bench plant expansion to increase production of methylene malonate monomers and oligomers. , ... of Sirrus’ full-scale production facility, which is scheduled to break ground in 2019. ...
(Date:4/10/2019)... ... April 10, 2019 , ... ... into multiple agreements to help companies advance their innovations to clinical testing ... from synthetic biology companies that are gene editing therapeutic cells for advanced ...
Breaking Biology Technology:
Cached News: